Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin

Cancer Immunology, Immunotherapy

Volumn 59, Issue 5, 2010, Pages 737-746

  Sarnovsky, Robert ^a   Tendler, Tara ^a   Makowski, Matheusz ^a   Kiley, Maureen ^a   Antignani, Antonella ^a   Traini, Roberta ^a   Zhang, Jingli ^a   Hassan, Raffit ^a   FitzGerald, David J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody; Cholix; Exotoxin; Immunotoxin; Neutralization

Indexed keywords

CHOLERA TOXIN; CHOLERA TOXIN 40; EPITOPE; HYBRID PROTEIN; IMMUNOTOXIN; NEUTRALIZING ANTIBODY; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN 38; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOXIN ANTIBODY; UNCLASSIFIED DRUG; EXOTOXIN; TRANSFERRIN RECEPTOR;

ANIMAL CELL; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER CELL CULTURE; CELL ASSAY; CELL STRAIN L 929; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DOMAIN; RAJI CELL; SEQUENCE HOMOLOGY; SERODIAGNOSIS; STRUCTURAL HOMOLOGY; TOXIN ANALYSIS; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; BLOOD; CROSS REACTION; GENETICS; IMMUNOLOGY; MOLECULAR GENETICS; NEOPLASM; PSEUDOMONAS;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, NEUTRALIZING; BASE SEQUENCE; BLOTTING, WESTERN; CHOLERA TOXIN; CROSS REACTIONS; EXOTOXINS; HUMANS; IMMUNOTOXINS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PSEUDOMONAS; RECEPTORS, TRANSFERRIN; RECOMBINANT FUSION PROTEINS; SINGLE-CHAIN ANTIBODIES;

EID: 77950473461     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-009-0794-4     Document Type: Article

References (41)

1. Hudis CA (2007) Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357:39-51
2. Cheson BD, Leonard JP (2008) Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359:613-626
3. Hermann DM, Weiner LM (2007) Monoclonal antibodies in therapy of solid tumors. Surg Oncol Clin N Am 16:775-792, viii
4. Green DJ, Pagel JM, Pantelias A et al (2007) Pretargeted radioimmunotherapy for B-cell lymphomas. Clin Cancer Res 13:5598s-5603s
5. Rybak SM (2008) Antibody-onconase conjugates: cytotoxicity and intracellular routing. Curr Pharm Biotechnol 9:226-230
6. Liu XY, Pop LM, Vitetta ES (2008) Engineering therapeutic monoclonal antibodies. Immunol Rev 222:9-27
7. Singh Y, Palombo M, Sinko PJ (2008) Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem 15:1802-1826
8. Brumlik MJ, Daniel BJ, Waehler R et al (2008) Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy. Expert Opin Drug Deliv 5:87-103
9. Carter PJ, Senter PD (2008) Antibody-drug conjugates for cancer therapy. Cancer J 14:154-169
10. Goldenberg DM, Sharkey RM (2007) Novel radiolabeled antibody conjugates. Oncogene 26:3734-3744
11. Pastan I, Hassan R, FitzGerald DJ et al (2007) Immunotoxin treatment of cancer. Annu Rev Med 58:221-237
12. Kreitman RJ, Pastan. I (2006) Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol Oncol Clin North Am 20:1137-1151, viii
13. Ricart AD, Tolcher AW (2007) Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 4:245-255
14. Frankel AE, Kreitman RJ, Sausville EA (2000) Targeted toxins. Clin Cancer Res 6:326-334
15. Frankel AE, Neville DM, Bugge TA et al (2003) Immunotoxin therapy of hematologic malignancies. Semin Oncol 30:545-557
16. Pastan I, Hassan R, Fitzgerald DJ et al (2006) Immunotoxin therapy of cancer. Nat Rev Cancer 6:559-565
17. Schnell R, Borchmann P, Staak JO et al (2003) Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma. Ann Oncol 14:729-736
18. Schnell R, Staak O, Borchmann P (2002) A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 8:1779-1786
19. Frankel AE (2004) Reducing the immune response to immunotoxin. Clin Cancer Res 10:13-15
20. Messmer D, Kipps TJ (2005) Treatment of solid tumors with immunotoxins. Breast Cancer Res 7:184-186
21. Onda M, Beers R, Xiang L et al (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci USA 105:11311-11316
22. Onda M, Nagata S, FitzGerald DJ et al (2006) Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J Immunol 177:8822-8834
23. Posey JA, Khazaeli MB, Bookman MA et al (2002) A. phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors. Clin Cancer Res 8:3092-3099
24. Weldon JE, Xiang L, Chertov O et al (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 113(16):3792-3800
25. Kreitman RJ, Wilson WH, Bergeron K et al (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345:241-247
26. Hassan R, Bullock S, Premkumar A et al (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13:5144-5149
27. Hassan R, Williams-Gould J, Watson T et al (2004) Pretreatment with rituximab does not inhibit the human immune response against the immunogenic protein LMB-1. Clin Cancer Res 10:16-18
28. Knechtle SJ (2001) Treatment with immunotoxin. Philos Trans R Soc Lond B Biol Sci 356:681-689
29. Pai LH, FitzGerald DJ, Tepper M et al (1990) Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice. Cancer Res 50:7750-7753
30. Jorgensen R, Purdy AE, Fieldhouse RJ et al (2008) Cholix toxin, a novel ADP-ribosylating factor from Vibrio cholerae. J Biol Chem 283:10671-10678
31. Ogata M, Pastan I, FitzGerald D ( 1991 ) Analysis of Pseudomonas exotoxin activation and conformational changes by using monoclonal antibodies as probes. Infect Immun 59:407-414
32. Batra JK, Fitzgerald DJ, Chaudhary VK et al (1991) Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol Cell Biol 11:2200-2205
33. Purdy A, Rohwer F, Edwards R et al (2005) A glimpse into the expanded genome content of Vibrio cholerae through identification, of genes present in environmental strains. J Bacteriol 187:2992-3001
34. Buchner J, Brinkmann U, Pastan I (1992) Renaturation of a single-chain immunotoxin facilitated by chaperones and protein disulfide isomerase. Biotechnology (N Y) 10:682-685
35. Buchner J, Pastan I, Brinkmann U (1992) A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal Biochem 205:263-270
36. Kreitman RJ, Wilson WH, White JD et al (2000) Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 18:1622-1636
37. Dalsgaard A, Albert MJ, Taylor DN et al (1995) Characterization of Vibrio cgolerae non-O1 serogroups obtained from an outbreak of diarrhea in Lima, Peru. J Clin Microbiol 33:2715-2722
38. Chaudhary VK, Queen C, Junghans RP et al (1989) A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin. Nature 339:394-397
39. Brinkmann U, Pai LH, FitzGerald DJ et al (1991) B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc Natl Acad Sci USA 88:8616-8620
40. Matthews DJ, Goodman LJ, Gorman CM et al (1994) A survey of furin substrate specificity using substrate phage display. Protein Sci 3:1197-1205
41. Zdanovsky AG, Chiron M, Pastan I et al (1993) Mechanism of action of Pseudomonas exotoxin. Identification of a rate-limiting step. J Biol Chem 268:21791-21799